Skip to Main Content

Paper Details

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
22
2023
COPD, Eosinophil, blood eosinophil, chronic obstructive pulmonary disease, dupilumab, human, interleukin-13, interleukin-4, patients, respiratory symptoms, type 2 inflammation
Author NameAffiliation
George D YancopoulosUniversity of Alabama at Birmingham, Birmingham (S.P.B.) LungenClinic Grosshansdorf and Christian Albrechts University of Kiel, Airway Research Center North, German Center for Lung Research, University of Marburg, Baylor College of Medicine, Houston (N.A.H.) OK Clinical Research, King's College London, and Manchester University NHS Foundation Trust, University of Manchester, University of California, San Francisco (S.A.C.) the University of Ferrara, R.M.A.) and Regeneron Pharmaceuticals
  • 1 - 1

Datasets